Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 48,700 shares, a drop of 50.7% from the September 30th total of 98,700 shares. Based on an average trading volume of 2,400,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.4% of the company’s stock are sold short.

Windtree Therapeutics Trading Up 2.7 %

NASDAQ:WINT traded up $0.02 on Friday, hitting $0.86. 768,745 shares of the company’s stock traded hands, compared to its average volume of 779,458. The company has a market cap of $511,310.40, a PE ratio of -0.02 and a beta of 0.55. Windtree Therapeutics has a 1 year low of $0.66 and a 1 year high of $22.36. The firm has a 50-day moving average price of $3.80 and a 200-day moving average price of $4.69.

Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings data on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80). On average, research analysts forecast that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.